A paper at the National Bureau of Economic Research explores how patients in high-deductible health plans changed behavior in regard to drug use.
Read More
A report from the IMS Institute for Healthcare Informatics gives the firm's perspective on trends affecting the pharmaceutical industry.
Read More
The current issue of Health Affairs is focused on innovation in medical products, suggesting that it may be hindered by less funding and regulatory and reimbursement hurdles.
Read More
A paper from Elsevier explores reasons for the recent uptick in generic drug prices.
Read More
A Congressional Budget Office report examines the effects of competition among Part D plans in Medicare's prescription drug benefit.
Read More
A brief from the Centers for Disease Control examines reasons that adults may not have used medications as prescribed, which largely relate to costs.
Read More
Prescription drug analytics firm Truveris maintains an index of drug prices and regularly reports on trends.
Read More
The FDA approved a significant number of new compounds in 2014, with the 41 novel medicines being second only to 1996's number. The bad news is that many of these drugs are specialty medications with very high price tags.
http://in.reuters.com/article/2015/01/01/pharmaceuticals-approvals-idINL6N0UE2C120150101The Pharmacy Benefit Management Institute issues its annual report on prescription drug benefit design, with specialty drugs getting much of the attention.
Read More
Tufts Center for the Study of Drug Development regularly estimates the average cost to bring a new compound to the market and currently says that cost is $2.56 billion, more than double what it was 11 years ago.
http://www.bloomberg.com/news/2014-11-18/cost-to-develop-a-drug-more-than-doubles-to-2-56-billion.htmlThe 340B drug pricing program is under assault for misuse. Two recent Health Affairs studies examined dispensing patterns in 340B pharmacy programs and who is benefiting.
Read More
The current issue of Health Affairs carries several articles on specialty drugs, which have become the priority area for cost-control efforts for most health plans.
Read More
A report from Express Scripts provides an updated look at drug utilization by enrollees in exchange plans.
Read More
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at khroche@healthy-skeptic.com.
Apple Podcasts
Google Podcasts
Spotify
Overcast
PocketCasts
Radio Public
Stitcher
Anchor
RSS - Posts